Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this randomized, placebo-controlled, double-blind study are to 1)
assess whether or not Namzaric® improves cognitive function in cancer survivors who received
prior brain irradiation as part of their standard of care therapy and 2) assess the
feasibility of using a digital symptom tracking application focused on Health Related Quality
of Life (HRQoL) and cognition in cancer survivors who received brain irradiation. Exploratory
objectives include assessing longitudinally the effect of Namzaric® on Patient Reported
Outcomes (PROs) as reported in the clinic, including measures of health-related quality of
life, cognition, and financial toxicity and evaluating the safety and tolerability of
administering Namzaric® to cancer survivors who have received prior irradiation.